Erasca Investors Face Class Action Over Alleged Misleading Drug Data

The stock decline occurred in two rapid stages on April 27 and April 28, 2026, wiping out $11.59 per share. The drop followed disclosures that Revolution Medicines had sent a letter alleging patent infringement and trade secret misappropriation by Erasca. Furthermore, the company revealed a patient death involving pneumonitis during Phase 1 clinical trials and admitted that previous comparisons between ERAS-0015 and the competitor drug RMC-6236 were not based on direct head-to-head trials.

Law firm Levi & Korsinsky, LLP, which is managing the litigation, asserts that the company’s market value was artificially inflated by claims regarding the drug's superiority. These claims were presented at investor conferences and in SEC filings even as the company raised $258.8 million in a January 2026 stock offering. Shareholders seeking to participate in the recovery effort must file for lead plaintiff status by August 10, 2026. Participation in the lawsuit does not require upfront fees, as the case operates on a contingency basis.